NeuroSense Therapeutics Ltd. Stock-Based Compensation
NeuroSense Therapeutics Ltd. (NRSN) reported Stock-Based Compensation of $2.14 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-03-31
| Period end | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|
| 2025-12-31 | $2.14M 20-F · filed 2026-03-31 | |
| 2025-06-30 | $306.00K 6-K · filed 2025-08-01 | |
| 2024-12-31 | $557.00K 20-F · filed 2026-03-31 | |
| 2024-06-30 | $306.00K 6-K · filed 2025-08-01 | |
| 2023-12-31 | $1.54M 20-F · filed 2026-03-31 | |
| 2023-06-30 | $1.02M 6-K · filed 2024-09-30 | |
| 2022-12-31 | $1.73M 20-F · filed 2025-04-07 | |
| 2021-12-31 | $1.22M 6-K · filed 2024-06-17 |